Network proximity analysis as a theoretical model for identifying potential novel therapies in primary sclerosing cholangitis.
Autoimmune liver disease
Druggable genome
Genome-wide association studies
Hepatology
Network proximity analysis
Primary sclerosing cholangitis
Therapeutics
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
15
05
2023
accepted:
05
06
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
11
6
2024
Statut:
epublish
Résumé
Primary Sclerosing Cholangitis (PSC) is a progressive cholestatic liver disease with no licensed therapies. Previous Genome Wide Association Studies (GWAS) have identified genes that correlate significantly with PSC, and these were identified by systematic review. Here we use novel Network Proximity Analysis (NPA) methods to identify already licensed candidate drugs that may have an effect on the genetically coded aspects of PSC pathophysiology.Over 2000 agents were identified as significantly linked to genes implicated in PSC by this method. The most significant results include previously researched agents such as metronidazole, as well as biological agents such as basiliximab, abatacept and belatacept. This in silico analysis could potentially serve as a basis for developing novel clinical trials in this rare disease.
Identifiants
pubmed: 38862968
doi: 10.1186/s12920-024-01927-2
pii: 10.1186/s12920-024-01927-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Subventions
Organisme : Wellcome Trust
ID : 219424/Z/19/Z
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547–59.
pubmed: 29452711
doi: 10.1016/S0140-6736(18)30300-3
Beuers U, Spengler U, Kruis W, Aydemir Ü, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–14.
pubmed: 1505913
doi: 10.1002/hep.1840160315
Chazouillères O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990;11(1):120–3.
pubmed: 1975818
doi: 10.1016/0168-8278(90)90281-U
O’brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991;14(5):838–47.
pubmed: 1937390
doi: 10.1002/hep.1840140516
Lindor KD. Ursodiol for primary sclerosing Cholangitis. N Engl J Med. 1997;336(10):691–5.
pubmed: 9041099
doi: 10.1056/NEJM199703063361003
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-Year Multicenter, Randomized, controlled study. Gastroenterology. 2005;129(5):1464–72.
pubmed: 16285948
doi: 10.1053/j.gastro.2005.08.017
Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing Cholangitis. Hepatol Baltim Md. 2009;50(3):808–14.
doi: 10.1002/hep.23082
Maria ND, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology. 1996;43(12):1472–9.
pubmed: 8975951
Phunchai Charatcharoenwitthaya P, Angulo FB, Enders KD, Lindor. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008;47(1):133–42.
pubmed: 17992695
doi: 10.1002/hep.21960
Ewa Wunsch J, Trottier M, Milkiewicz J, Raszeja-Wyszomirska GM, Hirschfield O, Barbier, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60(3):931–40.
pubmed: 24519384
doi: 10.1002/hep.27074
Mitchell SA, Bansi DS, Hunt N, Bergmann KV, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121(4):900–7.
pubmed: 11606503
doi: 10.1053/gast.2001.27965
Van Hoogstraten HJF, Wolfhagen FHJ, van de Meeberg PC, Kuiper H, Nix GAJJ, Becx MCJM, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol. 1998;29(3):417–23.
pubmed: 9764988
doi: 10.1016/S0168-8278(98)80059-7
Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 1994;20(1):57–64.
pubmed: 8201224
doi: 10.1016/S0168-8278(05)80467-2
Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008;48(5):792–800.
pubmed: 18314215
doi: 10.1016/j.jhep.2007.12.023
Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(5):1558–62.
pubmed: 11374699
doi: 10.1111/j.1572-0241.2001.03777.x
He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct ligated rats and human hepatic cells. Hepatol Baltim Md. 2011;53(2):548–57.
doi: 10.1002/hep.24047
Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37(6):604–12.
pubmed: 23384404
doi: 10.1111/apt.12232
Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, et al. Open-label prospective therapeutic clinical trials: oral Vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55(8):941–50.
pubmed: 32633158
doi: 10.1080/00365521.2020.1787501
Damman JL, Rodriguez EA, Ali AH, Buness CW, Cox KL, Carey EJ, et al. Review article: the evidence that Vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;47(7):886–95.
pubmed: 29411404
doi: 10.1111/apt.14540
Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepato-Biliary-Pancreat Sci. 2015;22(10):766–70.
doi: 10.1002/jhbp.281
Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549–58.
pubmed: 28529147
doi: 10.1016/j.jhep.2017.05.009
Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73(1):94–101.
pubmed: 32165251
pmcid: 8157171
doi: 10.1016/j.jhep.2020.02.033
Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356–78.
pubmed: 31154395
doi: 10.1136/gutjnl-2018-317993
Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.
pubmed: 20101749
doi: 10.1002/hep.23294
EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806.
doi: 10.1016/j.jhep.2022.05.011
Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabási AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.
pubmed: 30002366
pmcid: 6043492
doi: 10.1038/s41467-018-05116-5
Cordell HJ. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun. 2015;12.
Home. - ClinicalTrials.gov [Internet] [cited 2021 Mar 3]. https://clinicaltrials.gov/ct2/home .
Guney E. emreg00/proximity [Internet]. 2023 [cited 2024 Apr 10]. https://github.com/emreg00/proximity .
Guney E, Menche J, Vidal M, Barábasi AL. Network-based in silico drug efficacy screening. Nat Commun. 2016;7(1):10331.
pubmed: 26831545
pmcid: 4740350
doi: 10.1038/ncomms10331
Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601–1257601.
pubmed: 25700523
pmcid: 4435741
doi: 10.1126/science.1257601
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(Database issue):D1074–82.
pubmed: 29126136
doi: 10.1093/nar/gkx1037
Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57(2):366–75.
pubmed: 22521342
pmcid: 3399030
doi: 10.1016/j.jhep.2012.03.031
Wang MH, Fiocchi C, Zhu X, Ripke S, Kamboh MI, Rebert N, et al. Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet. 2014;133(5):547–58.
pubmed: 24241240
doi: 10.1007/s00439-013-1395-z
Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatol Baltim Md. 2013;58(3):1074–83.
doi: 10.1002/hep.25977
Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45(6):670–5.
pubmed: 23603763
pmcid: 3667736
doi: 10.1038/ng.2616
Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, et al. Genome-Wide Association Analysis in primary sclerosing Cholangitis. Gastroenterology. 2010;138(3):1102–11.
pubmed: 19944697
doi: 10.1053/j.gastro.2009.11.046
Srivastava B, Mells GF, Cordell HJ, Muriithi A, Brown M, Ellinghaus E, et al. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol. 2012;47(7):820–6.
pubmed: 22554193
doi: 10.3109/00365521.2012.682090
Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, MuriBoberg K et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARD9. Hepatol Baltim Md. 2011;53(6):1977–85.
Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269–73.
pubmed: 27992413
doi: 10.1038/ng.3745
Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510–8.
pubmed: 26974007
pmcid: 4848113
doi: 10.1038/ng.3528
Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, et al. An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs. J Hepatol. 2021;75(3):572–81.
pubmed: 34033851
pmcid: 8811537
doi: 10.1016/j.jhep.2021.04.055
Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–86.
pubmed: 15565569
doi: 10.1002/hep.20457
Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, Fischer L, Vig P, et al. Efficacy and Safety of Cenicriviroc in patients with primary sclerosing Cholangitis: PERSEUS Study. Hepatol Commun. 2021;5(3):478–90.
pubmed: 33681680
doi: 10.1002/hep4.1619
Carey EJ, Eaton J, Clayton M, Gossard A, Iqbal S, Ullah H, et al. A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis. Hepatol Commun. 2022;6(7):1589–97.
pubmed: 35238498
pmcid: 9234677
doi: 10.1002/hep4.1926
Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64(1):189–99.
pubmed: 26597786
doi: 10.1002/hep.28359
Paziewska A, Habior A, Rogowska A, Zych W, Goryca K, Karczmarski J et al. A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Med Genomics [Internet]. 2017 Jan 6 [cited 2020 Dec 3];10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217265/ .
Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43(1):17–9.
pubmed: 21151127
doi: 10.1038/ng.728
Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. 2017;24(1):e56–63.
pubmed: 24914504
pmcid: 4261045
doi: 10.1097/MJT.0000000000000102